Navigation Links
Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
Date:3/7/2013

KANSAS CITY, Kan. and BOSTON, March 7, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $10 million non-dilutive financing with Square 1 Bank, a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion.  Proceeds will be used to fund general corporate purposes. 

"We are delighted to have the continued support of Square 1 Bank," stated Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics.  "We're grateful Square 1 has remained a supporter of Aratana since its inception and are eager to extend our relationship as we advance our programs."

Scott Foote , senior vice president in Square 1 Bank's Life Sciences practice, added, "We are pleased to provide Aratana with the financing solutions it needs to support future developments in the animal health market, and we look forward to the company's future success."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

About Square 1 Bank

Square 1 Bank is a full service commercial ban
'/>"/>

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. Nasseo, Inc. Joins BioInspire™ Medical Technology Incubator, Closes Seed Funding Round
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Enviva Closes on $120 Million Senior Secured Credit Facility
8. AyoxxA Biosystems Closes Series A Financing Round
9. OncoSec Closes $7.75 Million Public Offering
10. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 1, 2011 Investor Uprising ( www.investoruprising.com ) has ... guide to the best biotech Exchange Traded Funds (ETFs) ... users of the Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) ... ongoing biotech bull market, identifying the leading biotech mutual ...
... June 1, 2011 Aaron Mitchell, managing principal at global ... top 25 consultants of 2011 by Consulting Magazine. Mitchell was ... biotech firm over several years and during a major, recent ... one of the top consultants," said Mitchell, who has more ...
... June 1, 2011 Reportlinker.com announces that ... in its catalogue: Osteosarcoma ... to 2017 http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
Cached Biology Technology:Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... list of 235 planthoppers from Iran is recorded along with ... Iranian Auchenorrhyncha during last 100 years. In addition to the ... transferring one species at family level is proposed. The study ... . Planthoppers are studied relatively little, but are ...
... on Centers for Disease Control and Prevention and other ... 30 years, we recognize the importance of reaching our ... with teachers having to incorporate more and more learning ... leave room for nutrition education in elementary schools? ...
... antibody developed by MassBiologics of the University of Massachusetts ... C virus (HCV) infection undergoing liver transplantation significantly suppressed ... and delayed the time to viral rebound. Results from ... this week at The Liver Meeting, the annual meeting ...
Cached Biology News:Cooking in the classroom to fight childhood obesity 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: